NEWS
undefined

undefined

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

In Jan, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA.

24

2024

/

01

Ketoprofen Cataplasms authorized by National Healthcare Security Administration, on NRDL

Ketoprofen Cataplasms authorized by National Healthcare Security Administration, on NRDL

At the end of 2023, National Healthcare Security Administration announced the results of the adjustment of NRDL (The National Reimbursement Drug List, NRDL was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments.), there are 126 drugs newly added. Jiudian Pharmaceutical's exclusive dosage form Ketoprofen Cataplasms is one of them. The new NRDL will be officially implemented on January 1, 2024.

13

2023

/

12

Jiudian Hongyang Pharmaceutical have Market Authorization of Ketoprofen API from NMPA

Jiudian Hongyang Pharmaceutical have Market Authorization of Ketoprofen API from NMPA

On 5th Dec, 2023, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Ketoprofen (Y20220000371) API from NMPA.

06

2023

/

12

Jiudian Hongyang Pharmaceutical obtained registration No. of Avobenzone and Sucralose from NMPA

Jiudian Hongyang Pharmaceutical obtained registration No. of Avobenzone and Sucralose from NMPA

Jiudian Hongyang, which is wholly-owned subsidiary of Jiudian Pharmaceutical, obtained registration No. of Avobenzone (F20230000420) and Sucralose (F20230000345) from NMPA in Oct, 2023.

25

2023

/

10

Hunan Jiudian Pharmaceutical have Market Authorization of Loxoprofen Sodium Oral Solution from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Loxoprofen Sodium Oral Solution from NMPA

Oct 24, 2023, Jiudian Pharmaceutical have drug license of Loxoprofen Sodium Oral Solution from NMPA. We are the first company which obtain it.

25

2023

/

10

Jiudian Hongyang Pharmaceutical had Market Authorization of Flurbiprofen from NMPA

Jiudian Hongyang Pharmaceutical had Market Authorization of Flurbiprofen from NMPA

On 29th Aug, 2023, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had market authorization of Flurbiprofen (Y20200001121) from NMPA.

31

2023

/

08

Jiudian Hongyang Pharmaceutical obtained registration No. of Polaprezinc from NMPA

Jiudian Hongyang Pharmaceutical obtained registration No. of Polaprezinc from NMPA

Jiudian Hongyang, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had registration no. of Polaprezinc (Y20230000678) from NMPA recently.

31

2023

/

08

Jiudian Pharmaceutical Semi-annual Report

Jiudian Pharmaceutical Semi-annual Report

On August 16, Jiudian Pharmaceutical released its 2023 half-year performance report. In the first half of the year, the company realized operating income of 1.218 billion RMB, an increase of 18.11% year-on-year; attributable net profit of 198 million RMB, an increase of 52.29% year-on-year, of which non-deductible attributable net profit of 178 million RMB, an increase of 43.35% year-on-year. The performance report shows that the company's various operating indicators are performing well, and continue to maintain a steady growth trend.

16

2023

/

08

< 1...12131415 >

Hunan Jiudian

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China     TEL. 0086-731-88220222     

1

Business license

Powered by：CEglobal   Privacy policy